Navigation Links
Angioslide Named One of Israel's Top Ten Most Promising Startups of 2011
Date:11/7/2011

CAESAREA, Israel, November 7, 2011 /PRNewswire/ --

Angioslide, a provider of Embolic Capture Angioplasty solutions, announced today that it has been named one of Israel's top ten most promising startups of 2011. The award was presented to Angioslide during the Ernst & Young (E&Y) Journey 2011 conference, held in Tel Aviv -  one of Israel's leading technology conferences, featuring prominent technology, healthcare and cleantech companies.  

"We are proud and honored to receive this award," said Lihu Avitov, CEO of Angioslide.  "Angioslide's innovative technology enables physicians to perform intravascular interventions while simultaneously providing embolic protection without the use of additional devices.   We have an early and growing group of physicians who are integrating our products into their standard of care for treating difficult lesions in peripheral vascular disease. We are focused on providing our clients with a full range of products and expanding adoption of our products around the world."

"The Angioslide PROTEUS™ catheter is a unique and proprietary device that combines balloon angioplasty and embolic capture, "said Mike Berman, a board member of Angioslide.  "Physicians are increasingly recognizing the potential of the PROTEUS to treat complex peripheral vascular disease."

Over 18 million people suffer from peripheral artery disease in the US alone. In recent years catheter-based interventions have become the primary therapeutic approach for these patients.  With the increase in life expectancy, diabetes prevalence, and number of high-risk patients, physicians are seeking to expand the current interventional "tool box" to improve procedure outcomes. Angioslide's PROTEUS device, combining a Percutaneous Transluminal Angioplasty (PTA) balloon and embolic capture of particles in one device, addresses this need.

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company that developed a unique Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic capture. The PROTEUS device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic particle capture solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs. The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, with regional offices in Europe and the US. For more information visit our website at http://www.angioslide.com

Contact:
Shira Doron
Marketing Director
Mobile: +972-54-9011134
shirad@angioslide.com

 



'/>"/>
SOURCE Angioslide Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. William F. Prendergast Named One of the Top IP Lawyers in Nanotechnology
2. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
3. Bill Pollock, President and CEO of Pharmagistics Group, Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences
4. Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area
5. IDIS Opens New American Office in Response to Industrys Growing Need for Pre-Launch Named Patient Programs
6. Baxa Corporation Named to Inc. 5000 for Second Consecutive Year as One of the Fastest-Growing Private Companies in the US
7. Stoppert Named as President and CEO at Breakthrough Renewable Technology Firm Segetis, Inc
8. Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN(R)
9. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
10. Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
11. NovaVision CEO Named Presenter at the AdvaMed 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... NX Prenatal Inc., a US based ... for early warning of adverse pregnancy outcomes, announced ... by Dr. Thomas McElrath of Brigham ... Medicine,s (SMFM) annual meeting held in ... The presentation reported initial positive top-line results regarding ...
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... ... 2016 , ... Benchmark Research, a fully-integrated network of ... principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research and ... Chu, a Benchmark Research PI in the Austin office, will assume the role ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC ... support program, Sonalinkā„¢ remote monitoring. The inaugural launch of this new technology occurred ... connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
Breaking Biology News(10 mins):